Latest COVID-19 News
ACR COVID-19 Town Hall: New Questions and Controversies for Patients with Rheumatic Diseases
The ACR hosted a virtual town hall for the rheumatology community on January 19 to address new questions and controversies concerning COVID-19 for your patients. A panel of infectious disease experts addressed topics, including pre-and post-exposure monoclonal antibody therapy, oral antiviral therapy, and vaccines for rheumatology patients.
Watch Town Hall Recording
Guiding Principles for Scarce Resource Allocation During the COVID-19 Pandemic
Tocilizumab
The ACR has released recommendations regarding the allocation of IV tocilizumab. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
View Tocilizumab Recommendations
Long-Acting Monoclonal Antibodies for Pre-Exposure Prevention of COVID-19
The ACR has released recommendations regarding the allocation of tixagevimab and cilgavimab injection for pre-exposure prevention of COVID-19. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
View ACR Recommendations
COVID-19 Vaccine Clinical Guidance
The ACR has developed new guidance for rheumatology providers on the use of the COVID-19 vaccines for patients with rheumatic and musculoskeletal diseases. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Vaccine Clinical Guidance Summary - Version 4 Revised - Updated December 15, 2021
COVID-19 Clinical Guidance for Pediatric Patients with MIS-C Associated with SARS-CoV-2 and Hyperinflammation in COVID-19
The ACR has developed guidance regarding immunomodulatory treatment in MIS-C and hyperinflammation in COVID-19, as well as statements on thrombotic risk and anticoagulation in MIS-C. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Clinical Guidance Summary – Version 3 – Updated October 19, 2021
See All Breaking COVID-19 News
Practice and Advocacy Resources
The ACR’s COVID-19 Practice and Advocacy Task Force continues to work rapidly to provide support to you during this unprecedented time. You’ll find guidance documents that include approaches to drug shortages, support for telehealth, information about federal stimulus relief aid, and guidance for infusions. Working with experts in COVID-related topics, we are focused on developing meaningful information and resources to help guide you.
Practice and Advocacy Resources
COVID-19 Manufacturer Resources and Patient Assistance Programs
COVID-19 Vaccine Clinical Guidance
The ACR has developed new guidance for rheumatology providers on the use of the COVID-19 vaccine for patients with rheumatic and musculoskeletal diseases (RMDs). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
COVID-19 Vaccine Clinical Guidance
Clinical Guidance for Pediatric Patients
The ACR has developed two new clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic, including for the care of children with pediatric rheumatic disease, and for the management of inflammatory syndromes in children with recent or concurrent infections with SARS-CoV-2, specifically Multisystem Inflammatory Syndrome in Children (MIS-C). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Clinical Guidance for Pediatric Patients
Clinical Guidance for Adult Patients with Rheumatic Diseases
The ACR has developed clinical guidance for the care of adult patients with rheumatic diseases during the COVID-19 pandemic. Populations considered include patients with a documented COVID-19 infection, those who are stable following exposure to SARS-CoV-2 (but without known infection), and patients who are stable with no infection or exposure. The recommendations address various treatment options and provide general guidance, as well as direction for when to start, stop, or reduce medications. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.
Clinical Guidance for Adult Patients with Rheumatic Diseases